Hematology-Oncology
Latest news
269 articles · 20 / page
Resminostat Maintenance Therapy Significantly Delays Disease Progression in Advanced Cutaneous T-Cell Lymphoma
The RESMAIN trial demonstrates that resminostat maintenance therapy doubles median progression-free survival in patients with advanced mycosis fungoides or Sézary syndrome, offering a potential new standard for managing patients who have ac
CPX-351 Benefit in AML is Driven by Myelodysplasia-Related Mutations: Insights from a Phase 3 Molecular Re-analysis
A molecular re-evaluation of the pivotal CPX-351 phase 3 trial reveals that its survival benefit is selectively confined to patients with myelodysplasia-related mutations (AML-MR), with no significant advantage over standard 7+3 induction i
Fractionated Dosing of Varnimcabtagene Autoleucel Delivers Deep Remissions and Enhanced Safety in Adult B-ALL
The CART19-BE-02 phase 2 trial demonstrates that varnimcabtagene autoleucel, utilizing a unique fractionated dose escalation strategy, achieves an 84.4% MRD-negative complete response rate in adults with relapsed or refractory B-ALL while s
Beyond Standard Staging: A Novel Genetics-Based Model Refines Prognosis for AML Patients Treated with Venetoclax and Hypomethylating Agents
A newly developed prognostic model integrates mutational and cytogenetic data to accurately predict survival in AML patients receiving HMA/VEN therapy, offering superior risk stratification into low-, intermediate-, and high-risk categories
Beyond the Count: How Product Factors and High Thresholds Shape Pediatric Platelet Transfusion Outcomes
A multicenter cohort study of 8,874 pediatric patients reveals that most prophylactic platelet transfusions occur above recommended thresholds. Factors such as pathogen reduction, additive solutions, and donor age significantly lower posttr
Redefining Anticoagulation Safety in the Elderly: Abelacimab Drastically Reduces Bleeding Risk in Phase 2b AZALEA-TIMI 71 Analysis
A prespecified analysis of the AZALEA-TIMI 71 trial demonstrates that the Factor XI inhibitor abelacimab significantly reduces bleeding risk compared to rivaroxaban in older patients with atrial fibrillation, potentially offering a safer al
Adjuvant Carboplatin Integration Redefines Survival Standards in Early-Stage Triple-Negative Breast Cancer: Insights from the RJBC 1501 Phase III Trial
The RJBC 1501 Phase III trial demonstrates that adding carboplatin to adjuvant EC-T chemotherapy significantly improves disease-free, distant disease-free, and overall survival in early-stage TNBC patients, despite a manageable increase in
Venetoclax-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: A Critical Appraisal of the Phase III CANOVA Study
The Phase III CANOVA trial evaluated venetoclax-dexamethasone against pomalidomide-dexamethasone in t(11;14)-positive RRMM. While the primary endpoint of progression-free survival was not statistically met, the study revealed significant im
Beyond the CNS and Skeleton: HSPC-Gene Therapy (OTL-203) Demonstrates Superior Multi-System Efficacy in Hurler Syndrome
A clinical study comparing OTL-203 gene therapy to allogeneic HSCT for Hurler syndrome reveals significant improvements in corneal clarity, hearing preservation, and cardiac stability, marking a potential shift in the standard of care for m
Rogocekib Demonstrates Clinical Activity as a First-in-Class CLK Inhibitor in Relapsed or Refractory AML and MDS
This Phase 1 study evaluates rogocekib, a novel CDC2-like kinase inhibitor, in patients with relapsed or refractory hematologic malignancies, reporting manageable safety and significant complete remission rates in AML and MDS cohorts, signa
Iptacopan: A Comprehensive Clinical Review of the First-in-Class Oral Factor B Inhibitor for PNH and Complement-Mediated Nephropathies
This review synthesizes clinical trial evidence for Iptacopan, focusing on its transformative role in treating PNH through proximal complement inhibition and its emerging efficacy in IgA nephropathy and C3 glomerulopathy.
Iptacopan Demonstrates Clinical Efficacy in Cold Agglutinin Disease While Falling Short in Immune Thrombocytopenia: Results from a Phase 2 Basket Trial
This Phase 2 basket trial highlights the divergent efficacy of the oral factor B inhibitor iptacopan, showing significant hemoglobin improvements in Cold Agglutinin Disease but failing to meet platelet response endpoints in Immune Thrombocy
Colchicine May Curb the Expansion of Pro-Inflammatory Clonal Hematopoiesis: Insights From the LoDoCo2 Substudy
A substudy of the LoDoCo2 trial suggests that low-dose colchicine may attenuate the expansion of specific clonal hematopoiesis driver mutations, particularly TET2, offering a potential mechanism for reducing cardiovascular risk by slowing t
Epcoritamab Monotherapy Demonstrates Potent Antitumor Activity in Richter Transformation: Insights from EPCORE CLL-1
The EPCORE CLL-1 trial evaluated epcoritamab, a CD3×CD20 bispecific antibody, in patients with Richter transformation. While the 47.6% overall response rate narrowly missed the 50% target, the results highlight a significant therapeutic sig
Intravenous Iron Outperforms Oral Prophylaxis in Non-Anaemic Iron-Deficient Pregnancy: A Paradigm Shift in Antenatal Care?
This multicentre RCT found that intravenous iron significantly boosts maternal hemoglobin before delivery in non-anaemic iron-deficient women compared to standard oral prophylaxis, highlighting the potential benefit of early ferritin screen
Iberdomide-Based Oral Triple Therapy Extends Progression-Free Survival to 17.6 Months in Relapsed Multiple Myeloma: Results from the ICON Study
The phase 2 ICON trial reveals that iberdomide combined with low-dose cyclophosphamide and dexamethasone (IberCd) achieves a median PFS of 17.6 months in lenalidomide-refractory multiple myeloma. This all-oral regimen represents a significa
Engineering a Cure: How CAR T-Cell Therapy is Transforming the Fight Against Autoimmune Hemolytic Anemia
A groundbreaking study shows that CD19 CAR T-cell therapy can induce sustained, drug-free remission in patients with severe, multirefractory autoimmune hemolytic anemia by successfully eliminating the autoreactive B-cells that drive the dis
Tafasitamab Plus R2 Regimen Sets a New Benchmark for Relapsed or Refractory Follicular Lymphoma: Insights from the inMIND Trial
The Phase 3 inMIND trial demonstrates that adding tafasitamab to lenalidomide and rituximab (R2) significantly improves progression-free survival in patients with relapsed or refractory follicular lymphoma, reducing the risk of disease prog
Epcoritamab Plus R2 Redefines the Standard of Care in Relapsed or Refractory Follicular Lymphoma: Insights from the EPCORE FL-1 Trial
The Phase 3 EPCORE FL-1 trial demonstrates that adding epcoritamab to lenalidomide and rituximab (R2) significantly improves progression-free survival (HR 0.21) and response rates in relapsed/refractory follicular lymphoma, establishing a p
Model-Based ATG Dosing Successfully Accelerates CD4+ Reconstitution in CD34+ Selected Allogeneic HCT
A Phase 2 study demonstrates that pharmacokinetic model-based ATG dosing significantly enhances CD4+ T-cell reconstitution in patients undergoing CD34+ selected hematopoietic cell transplantation, reaching primary endpoints in 70% of partic
Browse by specialty
Open language-specific specialty feeds and department pages.